ALBUQUERQUE, N.M., August 16, 2023 (Newswire.com) - Eden Radioisotopes, LLC, (Eden) an Albuquerque, NM, company, has formally notified the U.S. Nuclear Regulatory Commission of its plans to submit license applications in order to construct and operate a medical isotope production facility near Eunice, Lea County, New Mexico. 

Eden's dedicated nuclear fission reactor and collocated hot cell processing facility will supply radioisotopes for both the diagnostic and therapeutic market segments, including Molybdenum-99, and Xenon-133, for medical imaging and Lutetium-177 and Iodine-131 for radiotherapeutic purposes. This new facility will initially focus on Molybdenum-99 and Lutetium-177, addressing expected future capacity shortfalls and complex supply chains that are increasingly challenged.

The Company is in the fast-growing molecular imaging industry, where radioactive substances are used in both diagnostic and targeted radiotherapeutic applications. The molecular imaging and radiotherapeutic market is predicted to reach $13.9 Billion by 2025, with the strongest growth from radiotherapeutics, such as Lutetium-177 for targeted prostate cancer treatment.

Medical isotopes are used in more than 40 million imaging procedures annually worldwide, of which 80 percent use Technetium-99m, derived from Molybdenum-99, to diagnose heart disease, cancer and other life-threatening conditions. The isotopes are injected into patients that can be tracked in the body, letting physicians create images that diagnose disease or provide specifically targeted treatment of various cancers, such as prostate cancer. 

"Using technology developed at Sandia National Laboratories to build the Eden reactor is important for helping to assure a future reliable supply of these critical isotopes to meet the needs of patients both now and for the next several decades. Eden is well positioned to be able to make Molybdenum-99, creating new capacity for the heritage diagnostic market segment, while also being able to make Lutetium-177 to meet future supply needs for the ground-breaking targeted radiotherapeutics market segment," said Chris Wagner, CEO, Eden Radioisotopes.

About Eden Radioisotopes, LLC (Eden)

Eden is leveraging science and innovation developed by Sandia National Laboratories to build a 2MW reactor in New Mexico for the future production of medical isotopes for both diagnostic molecular imaging and radiotherapeutic uses. Eden is committed to providing a reliable supply of medical isotopes such as Molybdenum-99 and Lutetium-177, along with other isotopes, for healthcare patients worldwide. 

www.edenrad.com

Contact Information:
Chris Wagner
CEO
[email protected]
Related Files
Eden Radioisotopes, LLC Press Release_NRC License Application Filing v2 (8-14-23).docx



Original Source: Eden Radioisotopes, LLC Notifies the US Nuclear Regulatory Commission of Plans to Submit License Applications to Construct and Operate a Medical Isotope Production Facility

Radical Imaging Partners with Medicai to Provide an All-in-One Medical Imaging Infrastructure, Workflows Management System and Viewer Solution

BOSTON, August 15, 2023 (Newswire.com) - Radical Imaging LLC, a pioneer in medical imaging informatics, interoperability, and integrations, announced today that it is partnering with Medicai, a provider of decentralized cloud-based infrastructure (PACS, VNA and exchange) that enables healthcare providers to seamlessly and securely manage and exchange imaging data. This partnership will enable Medicai's customers to easily opt-in to use FlexView as their viewer in Medicai's platform and FlexView's customers to have Medicai's ready-made solution when it is required that they use a central repository for medical images and associated patient data from multiple healthcare systems in conjunction with the viewer. 

FlexView is a professionally supported, SaaS cloud medical imaging viewer created by Radical Imaging that is based on the Open Health Imaging Foundation (OHIF) framework. It is a commercial-grade, production-ready solution that can easily be incorporated into any medical imaging system, seamlessly providing the viewing and analysis capabilities for any type of medical image or workflow. FlexView adds to OHIF's extensibility model by introducing the ability to deploy plugins at runtime. This is crucial to enable the addition of new features dynamically, such as AI-based tools, without causing disruptions or system downtime. Users will be able to discover, opt into and use these value-added services as they become available in the FlexView Extension Marketplace. FlexView will be available to the general public in September 2023.

Medicai's cloud-based platform provides physicians with instant access to patient medical images, such as X-rays, CT scans, and MRIs, and other relevant medical files, regardless of location. It enables them to view and analyze medical images, make diagnoses, and collaborate with other medical professionals across different healthcare settings in real-time to make more informed decisions about patient treatment. The platform is designed to be user-friendly and scalable, allowing healthcare providers to easily access and share imaging data across a network of providers.  

Medicai's interoperable medical imaging architecture enables seamless communication and data exchange between different medical imaging systems and healthcare applications, regardless of the vendor or technology used. The platform is built on industry-standard protocols, including DICOM and HL7, ensuring that it can easily integrate with other healthcare systems, such as Electronic Health Records (EHRs) and Picture Archiving and Communication Systems (PACS). A vendor-neutral archive (VNA) is included, which acts as a central repository for medical images and associated patient data, and supports various DICOM standards and image formats. A set of interfaces and APIs (Application Programming Interfaces) that enable different systems and applications to communicate with each other is also included, promoting interoperability and enabling more efficient workflows. 

"We are excited to have FlexView fully integrated into Medicai's platform on day one of our launch of FlexView. This integration will benefit both Medicai's existing customers and FlexView's future customers by having a best-in-class, all-in-one medical imaging infrastructure and viewer solution at the ready when required," said Rob Lewis, CEO of Radical Imaging.

About Radical Imaging LLC

Radical Imaging is a software company focused entirely on medical imaging. It offers software system design and planning, contract software development and consulting to help its partners solve their most challenging medical imaging problems using modern cloud and web platforms like Cornerstone.js and OHIF which it co-developed with Massachusetts General Hospital. In 2023, Radical Imaging will be releasing its first commercial product, FlexView, a commercial version of OHIF. For more information, visit RadicalImaging.com.

About Medicai

Medicai is an awarded suite of software systems for organizations working with medical imaging: imaging centers, hospitals, and specialized providers, offering fully secure and compliant imaging data management. Medicai's software components include: a cloud-native, decentralized medical imaging infrastructure and workflows management system, web and mobile applications for doctors and patients to collaborate on imaging data, and a cost-effective data archiving solution. For more information, please visit medicai.io.

Contact Information:
Radical Imaging
[email protected]


Original Source: Radical Imaging and Medicai Partner Together to Integrate FlexView in Medicai's Platform

Allure Esthetic's Mother's Day Drive in Seattle Donates Diapers, Supplies to Mary's Place

SEATTLE, August 15, 2023 (Newswire.com) - In the lead-up to Mother's Day 2023, Seattle plastic surgeon Dr. Javad Sajan's practice, Allure Esthetic Plastic Surgery, collected donations for mothers experiencing homelessness in the community. This included physical donations in the office and monetary donations directly to the Zera Foundation, the partnering nonprofit organization.

With collection boxes at all three locations, Dr. Sajan offered five free units of Botox to anyone who donated two or more items to the drive. Allure Esthetic frequently works with the 501c3 nonprofit, the Zera Foundation to make a difference in the lives of families in transition and underprivileged populations.

In a video about the fundraiser, Javad Sajan, MD says, "We're so excited to partner with our community to help people who are going through a difficult transition in life." Allure Esthetic also hosts other fundraising events throughout the year such as a Thanksgiving Food Drive and School Supplies Drive.

On July 22nd, Dr. Sajan hand-delivered the donations to Mary's Place, a shelter and organization that supports women and families, in Seattle. The donations consisted of diapers, wipes, and other items necessary for mothers and children of all ages. All donations stay within the community and uplift women and children in need.

About Javad Sajan, MD: Javad Sajan, MD is a plastic surgeon in Seattle, Washington. His practice Allure Esthetic Plastic Surgery provides plastic surgery and life-saving gender affirming surgery to patients from all around the world. Allure Esthetic and Javad Sajan, MD regularly participate in the community through item collection drives and fundraisers that benefit families and children in the Great Seattle area. Find Dr. Sajan, Allure Esthetic, and their community service efforts on Instagram @realdrseattle.

Contact Information:
Allure Esthetic
[email protected]
206-209-0988


Original Source: Washington Plastic Surgeon Javad Sajan, MD, Donates to Homeless Women After Successful Mother's Day Drive at Allure Esthetic

Updates to Tempo's Manufacturing Execution System and Connected Manufacturing Network Drive Greater Efficiency and Scalability

JERSEY CITY, N.J., August 15, 2023 (Newswire.com) - Apprentice, which helps life science manufacturers get treatments to patients faster by providing one platform to turn molecules into medicine, announced today a major release to its Tempo Manufacturing Cloud, focused on extending product capabilities for modern commercial manufacturing.

The 7.0 Release deepens Tempo's existing features in its Manufacturing Execution System (MES) that support commercial production and adds a new product, the Connected Manufacturing Network (CMN), that creates a connected digital network across internal and external sites. 

Deepening Manufacturing Execution System (MES) Capabilities

"We want to help our customers navigate today's complex manufacturing environment as drug therapies become more specialized and scalability becomes more important," said Angelo Stracquatanio, CEO & Co-founder of Apprentice.io. "With the 7.0 release, we're building the technological innovation that will directly reduce cost, increase speed, and maximize yield of commercial manufacturing so that lifesaving medicines get to patients in need."

In addition to 30+ new features and enhancements, seven key new capabilities standout:

• Visual step builder: Develop complex procedure workflows through a click-and-drag visual flow of steps for easier process design for scientists.
• Kitting: Use and consume predefined resource sets instead of searching for individual components in order to streamline procedures and save valuable time.
• Automatic step execution: Execute actions within a procedure step, such as calculations or scanning equipment, in addition to creating steps that connect to other equipment or even other systems with in-step integration.
• Remote Assistance: Adapt to constant change during execution and drive faster reviews with real-time embedded video conferencing from a procedure run.
• Conditional Step Navigation: Guide an operator to one of several procedure step options using 'if', 'if then', or 'else' statements based on the result of the previous step.
• New integrations:  Start batch runs directly from an External DCS to support automated batch runs.
• Web execution: Gain greater operational flexibility with the new ability to execute from your web browser, in addition to Tempo's iPad and wearable headset.

The Connected Manufacturing Network

The 7.0 release also includes the new CMN product. Tempo's CMN enables you to drive value at the site-level, the enterprise-level, and across external partners. To achieve this, CMN brings together four powerful capabilities:

• Product Lifecycle Data: Consolidate data for each stage of a drug's lifecycle in one place.
• Enterprise Recipe Management: Optimize enterprise recipe management across environments and sites.
• External Manufacturing Collaboration: Ditch email and calls for automated communications.
• Tech Transfer: Quickly and easily move all your master resources and data.

These key tools allow you to coordinate the materials, equipment, recipes, and personnel needed to plan, execute, test, and release a batch from one shared system to accelerate the end-to-end drug production lifecycle.

Launching Tempo with the Team

Apprentice held a virtual launch event on Tuesday with 100+ attendees highlighting the new commercial functionality and the success of its recently released CMN package.

Event sessions covered everything from Apprentice's more sophisticated commercial manufacturing capabilities to its new quarterly release cadence, additional quality updates, and the formation of its partner program. 

"We have a clear vision for building a product that can support the future of commercial manufacturing and connect enterprise-wide operations across internal and external sites and teams," said Jean Barmash, CTO at Apprentice. "We will continue to up-level our product capabilities and standardize our approach so that our customers can rely on one system for accelerating critical drug production."

About Apprentice

Apprentice helps life science manufacturers get therapeutics to patients faster by providing one platform to turn molecules into medicine. Our Tempo Manufacturing Cloud accelerates the end-to-end drug product lifecycle by connecting together distributed teams and sites, helping them execute better on the shop floor, and optimizing their operations through enterprise-wide visibility. From preclinical benchtop to large-scale commercial manufacturing, Tempo keeps your global teams connected, empowered, and in sync. 

With $207M in funding, a 3.4x growth YoY rate, and 218% net customer retention, Apprentice is a trusted partner to modernize your operations and change the way drugs are made in your facility. Learn how leading companies like Synthego and Bristol Myers Squibb are using Tempo to scale from drug discovery to patient delivery faster at www.apprentice.io.

Contact Information:
Marie Forshaw
VP, Marketing
[email protected]

Kristen Kucks
Director of Communications, Marketing
[email protected]


Original Source: Apprentice Announces Major Tempo Manufacturing Cloud Release Built to Support Commercial Manufacturing of the Future

Elevating Community Health: August Marks National Immunization Month, a Time to Raise Awareness and Promote Lifesaving Vaccinations. LevelUp MD Urgent Care Encourages Keeping Immunization Records Up-to-Date.

BROOKLYN, N.Y., August 15, 2023 (Newswire.com) - LevelUp MD Urgent Care is proud to join the nationwide observance of National Immunization Awareness Month (NIAM), a critical initiative that underscores the paramount importance of vaccinations for individuals of all ages. Throughout August, we are committed to raising awareness about the crucial role vaccines play in safeguarding public health and maintaining the well-being of our communities.

Vaccinations stand as one of the most impactful achievements in modern medicine, offering unparalleled protection against preventable diseases. National Immunization Month serves as a vital reminder that vaccines are not only a personal responsibility but a collective effort to build immunity, reduce illness, and promote longevity. By administering routine vaccinations, we contribute to the health and resilience of our society as a whole.

"At LevelUp MD Urgent Care, we recognize the significance of immunizations as a cornerstone of preventive healthcare. National Immunization Awareness Month provides us with an opportunity to amplify the importance of vaccines and their role in keeping communities thriving," stated Dr. Jonathan Gamss, Chief Medical Director at LevelUp MD Urgent Care.

Our commitment to public health is evident through the array of vaccinations we offer at our conveniently located facilities in New York and New Jersey. Our comprehensive range of vaccines includes:

• TDAP
• Hepatitis B
• Meningitis
• MMR (Measles, Mumps, Rubella)
• Varicella
• MPOX (Mumps, Polio, Rubella)
• COVID-19 (Ages 6 months and up)
• Flu (Age 6 months and up)

"During National Vaccine Awareness Month and well into the future, our mission remains clear: to inform, inspire, and empower. Through educational initiatives, accessible resources, and collaborative engagement, we are actively working to fortify the health of our communities. By emphasizing the significance of vaccinations, we stand united in our commitment to building a healthier and more resilient tomorrow for everyone," says Rey Bolic, Director of Marketing and Community Outreach at LevelUp MD Urgent Care.

LevelUp MD Urgent Care boasts multiple accessible locations, making quality healthcare readily available to residents of New York and New Jersey:

• Bloomfield, NJ
• Emerson, NJ
• Passaic, NJ
• Crown Heights, Brooklyn, NY
• East Flatbush, Brooklyn, NY
• Park Slope, Brooklyn, NY
• Williamsburg, Brooklyn, NY
• The Hub, Bronx, NY
• Norwood, Bronx, NY
• Forest Hills, Queens, NY

During National Immunization Awareness Month and beyond, LevelUp MD Urgent Care remains dedicated to being a steadfast partner in promoting health and advocating for preventive care. By offering a variety of vaccines across our locations, we stand committed to protecting the well-being of our communities and inspiring a future where preventable diseases are conquered.

For more information about our services and locations, visit https://levelupuc.com/ 

Contact Information:
Rey Bolic
Director of Marketing
[email protected]
718-954-6741


Original Source: LevelUp MD Urgent Care Celebrates National Immunization Awareness Month: Promoting a Healthier Future Through Vaccination Advocacy

A New American Heart Association CPR Certification School Has Just Opened in Brentwood, CA. This School Offers Daily Classes to the Public in CPR, BLS, ACLS, PALS, and CPR and First Aid.

BRENTWOOD, Calif., August 15, 2023 (Newswire.com) - Safety Training Seminars, an official American Heart Association© (AHA) Training Center in California, is proud to announce the opening of their newest CPR training center at 380 Carrol Court, Suite G, Brentwood, CA 94513. The new CPR training center is centrally located near Antioch and Discovery Bay, making it easily accessible to healthcare professionals in Contra Costa County. The office is open every day of the week and courses are offered to the public during regular business hours. 

Safety Training Seminars' new Brentwood CPR Training School offers a comprehensive range of courses for medical professionals, including CPR, BLS, ACLS, and PALS. Each course provides an innovative blend of online learning resources and on-site skills testing, ensuring that participants are fully prepared to handle life-threatening emergencies. After the training, students will immediately receive the official American Heart Association certification card. 

ACLS Courses offer initial and renewal certification in American Heart Association Advanced Cardiovascular Life Support, providing participants with the skills and knowledge needed to respond to cardiopulmonary arrest or other cardiovascular emergencies. 

CPR & First Aid Classes are designed for a wide variety of participants, such as teachers, babysitters, childcare care providers (EMSA), supervisors, and more. Students will learn the proper techniques for administering CPR to infants, children, and adults, as well as how to use AEDs, treat bleeding, respond to seizures, and more. After completing the course, all students will receive the official American Heart Association CPR and First Aid certification. 

BLS CPR courses provide new and renewal certification, helping attendees identify and respond to life-threatening emergencies. After attending this course, students will receive the official American Heart Association BLS certification card, which is valid for two years. 

PALS Courses are designed to meet the criteria for initial or renewal certification and teach participants how to recognize and respond to emergencies in infants and children. PALS stands for Pediatric Advanced Life Support. 

Safety Training Seminars has been providing crucial courses for certification and lifesaving training since 1989. The woman-owned company has 45 locations across Northern California, and they offer the most affordable, flexible training, with the latest resources and equipment. With their new Brentwood CPR office, Safety Training Seminars is committed to equipping Contra Costa residents with the skills and confidence to react quickly in emergency situations. To learn more about CPR and First Aid training in Brentwood, Antioch, and other locations across California, visit www.bayareacpr.org.

Contact Information:
Danielle Bell
General Manager
[email protected]
415-437-1600


Original Source: Safety Training Seminars Opens a New American Heart Association CPR Training Center in Brentwood, CA

TORONTO, August 15, 2023 (Newswire.com) - StageZero Life Sciences ("StageZero" or the "Company") (TSX: SZLS), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its second quarter financial results for the three and six months ended June 30, 2023, and will provide an update on its business operations.

For the quarter ended June 30, 2023 the Company generated revenue of $0.793 million. This is a small increase over Q1 2023 but continues the trajectory established post-COVID of Quarterly gains. Net loss narrowed to ($0.401) with a ($0.00) basic and diluted loss per common share.

"This has been a quarter of negotiating and concluding key partnerships that we expect to contribute strongly to our growth during the second half of this year," said James Howard-Tripp, Chairman & CEO of StageZero Life Sciences. "A major focus is on self-funded employers where we believe Aristotle and AVRT uniquely position us, the insurance groups that back them, but also to position ourselves for new, exciting initiatives in Preventative Health. Our partners reflect this," he added.

Strategic partnerships with laboratory groups and clinical groups will increase the number of employers, clinics and individual patients who can readily access StageZero's Aristotle test and AVRT/TREAT programs. Individuals and Employers are increasingly looking for better health outcomes and early detection notably contributes to a better outcome. In addition, it contributes to lower costs which, for Employers, is a driving metric for their bottom line.

Operational Update: will be provided during Analyst Call.

Q2 2023 Financial Results

All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.

The Company generated $1.6 million in cancer testing and treatment revenue for the six months ended June 30, 2023 as compared to COVID testing-related $2.3 million in revenue for the six months ended June 30, 2022 and realized a net loss of $2.2 million, or $0.02 basic and diluted loss per common share as compared to a $1.9 million net loss for the six months ended June 30, 2022, or $0.02 basic and diluted loss per common share.

The Company generated $0.793 million in cancer testing and treatment revenue for the three- months ended June 30, 2023, compared to COVID testing-related revenue of $0.998 million for the three months ended June 30, 2022. Net loss was $0.4 million, or $0.00 loss per fully diluted common share in Q2, 2023 as compared to a $1.3 million net loss, or $0.01 loss per fully diluted common share in Q2, 2022.

The Company's financial statements and management's discussion and analysis are available on www.sedar.com.

Analyst and Investor Call
Event Date: Tuesday August 15, 2023
Time: 8:30 am ET
Webcast Link: https://www.gowebcasting.com/12674
Conference Call Numbers
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340

About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a company innovating on the forefront of screening for the early detection of cancer. StageZero combines its proprietary liquid biopsy multi-cancer detection test, Aristotle®, with Physician led clinical programs; offering patients a unique treatment combination not found anywhere else.

Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types. Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use.

The COC Protocol program is managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. CareOncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease.

Aristotle® is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Contact Information:
Rebecca Greco
Investor Relations
[email protected]
1.855.420.7140 ext. 1838


Original Source: StageZero Life Sciences, Ltd Announces Q2 2023 Financial Results and Operational Update